Alison M. Lehner
Alison Lehner represents not only large corporations and universities in a full range of transactional matters, but she also regularly works with growth-stage companies and venture capital investors.
As a member of the firm's Life Sciences Industry Group, she is part of a multidisciplinary team focused on providing a full spectrum of legal services to clients involved in the life sciences industry. Alison represents life sciences and technology companies as well as universities in a variety of licensing and partnering transactions.
Alison also handles mergers and acquisitions, equity and debt financings, joint ventures, licensing and collaborations, and corporate governance matters. Alison has represented clients in the acquisition and disposition of assets and securities, mergers, and other business combinations. She also represents private equity and venture capital funds and their portfolio companies in acquisition and financing transactions. In addition to advising on transactional matters, Alison provides corporate governance, securities, and compliance advice to public and private companies, institutions, and their boards.
While in law school, Alison was a member of the American University Law Review. She began her legal career as a summer associate at Hogan Lovells and as an intern for the Honorable Glenn T. Harrell, Jr. and the Honorable Clayton Greene, Jr. of the Maryland Court of Appeals.
Advised the University of Pennsylvania in the spin-out and licensing of T-cell immunotherapies and its collaboration with the Parker Institute for Cancer Immunotherapy.
Represented TESARO in its global prostate cancer collaboration and licensing agreement with Janssen Biotech.
Regularly advises New Enterprise Associates in its venture capital equity and debt financings for healthcare-related portfolio companies.
Represented a high-technology company in connection with its life sciences business ventures, including exclusive licenses and joint ventures.
Regularly advises TESARO and Rexahn Pharmaceuticals on corporate governance, commercial, and securities reporting matters.